<DOC>
	<DOCNO>NCT00661778</DOCNO>
	<brief_summary>This study assess efficacy safety Avastin combination docetaxel cisplatin first-line treatment patient metastatic locally advanced non-small cell lung cancer . Patients receive Avastin 15 mg/kg intravenously ( IV ) , docetaxel 75 mg/m^2 , cisplatin 75 mg/m^2 Day 1 3-week cycle maximum 6 cycle .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Combination With Docetaxel Cisplatin Patients With Metastatic Locally Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Adult patient , â‰¥ 18 year age . Stage IIIb IV nonsmall cell lung cancer . Chemotherapynaive . Previous treatment nonsmall cell lung cancer . Previous malignant tumor within last 5 year , except basal cell skin cancer preinvasive cervical cancer . Major surgical procedure , open biopsy , significant traumatic injury within 28 day prior start study . Recent current chronic treatment aspirin ( &gt; 325 mg/day ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>